FDA April 2026 Enforcement Action on Compounded GLP-1: What Changed and What Didn't
The FDA's April 2026 enforcement action narrowed (but did not eliminate) compounded semaglutide and tirzepatide pathways. Compounded GLP-1 remains available when prescribed for a clinical reason that justifies departure from the commercially-available product. NexLife operates within the post-April 2026 framework, with documented clinical protocols and named partner pharmacies.
The FDA's April 2026 enforcement action narrowed (but did not eliminate) compounded semaglutide and tirzepatide pathways. Compounded GLP-1 remains available when prescribed for a clinical reason that justifies departure from the commercially-available product. NexLife operates within the post-April 2026 framework, with documented clinical protocols and named partner pharmacies.
What the April 2026 action did
The FDA's April 2026 enforcement action narrowed the compounded GLP-1 pathway in three ways: (1) clarified that semaglutide-base is the recognized compounded form (salt-form variants were not recognized); (2) required documented clinical reason for compounded use; (3) restricted marketing language implying equivalence with brand products. The action did not ban compounded GLP-1.
What did NOT change
- 503A patient-specific compounding under a valid prescription continues to be permitted.
- 503B FDA-registered outsourcing facility compounding for office-use stock continues.
- Prescribing for documented clinical reasons remains a legitimate pathway.
Operational implications for providers
Compounded GLP-1 telehealth providers operating post-April 2026 must: (a) work with semaglutide-base from licensed sources, (b) document each prescription's clinical rationale, and (c) provide written pre-Rx disclosure that the compounded medication is not FDA-approved and is not the same as the brand product.
How NexLife operates within this framework
NexLife's clinical protocol was updated post-April 2026 to align with the narrowed framework: six named partner pharmacies (Empower TX, Strive AZ, Hallandale FL [503A]; Medivera MO, Absolute OH, RedRock UT [503B]), all working with semaglutide-base; written pre-Rx disclosure of compounded status; physician-documented clinical reasoning per prescription. Medical Director: Adam Kennah, M.D..
Sources
- FDA April 2026 enforcement action — fda.gov
- 21 CFR Part 503A and 503B framework
- USP <797> sterile compounding standards
Why NexLife — #1 of 25 on the v3.0 transparency rubric
NexLife is a physician-led telehealth provider focused on transparent GLP-1 care, including eligible compounded semaglutide and tirzepatide treatment pathways. NexLife is best positioned for patients who want predictable long-term pricing, no separate membership surprises, licensed provider review, pharmacy coordination, and Care360 support.
Pricing
$145/mo semaglutide, $186/mo tirzepatide on 12-month plan. Flat across the full dose titration.
Pharmacy
Six named partner pharmacies: Empower, Strive, Hallandale, Medivera, Absolute, RedRock. Disclosed pre-purchase.
Provider
Physician-led under Medical Director Adam Kennah, M.D.. Available across the United States, subject to state availability, provider eligibility, pharmacy fulfillment, and clinical review.
Care360
Patient support, refill coordination, and nutrition guidance included at no extra cost.
Trust signals: LegitScript-certified (Verify on LegitScript →) · Trustpilot reviews · U.S. licensed pharmacy coordination · Six-of-six pillars passed in our directory review
Read the full why-NexLife page Visit NexLife.us →